6-65494921-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001142800.2(EYS):c.490C>T(p.Arg164Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000143 in 1,613,940 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001142800.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
EYS | NM_001142800.2 | c.490C>T | p.Arg164Ter | stop_gained | 4/43 | ENST00000503581.6 | NP_001136272.1 | |
EYS | NM_001292009.2 | c.490C>T | p.Arg164Ter | stop_gained | 4/44 | NP_001278938.1 | ||
EYS | NM_001142801.2 | c.490C>T | p.Arg164Ter | stop_gained | 4/12 | NP_001136273.1 | ||
EYS | NM_198283.2 | c.490C>T | p.Arg164Ter | stop_gained | 3/10 | NP_938024.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EYS | ENST00000503581.6 | c.490C>T | p.Arg164Ter | stop_gained | 4/43 | 5 | NM_001142800.2 | ENSP00000424243 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152082Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251220Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135754
GnomAD4 exome AF: 0.0000144 AC: 21AN: 1461858Hom.: 0 Cov.: 31 AF XY: 0.0000179 AC XY: 13AN XY: 727224
GnomAD4 genome AF: 0.0000132 AC: 2AN: 152082Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74302
ClinVar
Submissions by phenotype
Retinitis pigmentosa 25 Pathogenic:5
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jul 08, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant (PVS1_VS). The variant has been reported at least twice as pathogenic/likely pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000197186, PMID:22581970). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000008, PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Sep 22, 2021 | The EYS c.490C>T (p.Arg164Ter) variant is a stop-gained variant that is predicted to result in a premature termination of the protein. The variant has been reported in a compound heterozygous state in at least five individuals, including two siblings, affected with retinitis pigmentosa (O'Sullivan et al. 2012; Chen et al. 2015; McGuigan et al. 2017). The variant is reported at a frequency of 0.000008 in the Total population of the Genome Aggregation database (version 2.1.1), though this is based on only two occurrences in a region of good sequence coverage, so the variant is presumed to be rare. Based on the collective evidence, the p.Arg164Ter variant is classified as pathogenic for autosomal recessive retinitis pigmentosa. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 28, 2024 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 12, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 22, 2023 | This sequence change creates a premature translational stop signal (p.Arg164*) in the EYS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EYS are known to be pathogenic (PMID: 18836446, 20333770). This variant is present in population databases (rs794727631, gnomAD 0.003%). This premature translational stop signal has been observed in individuals with retinitis pigmentosa (PMID: 22581970, 25753737). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 197186). For these reasons, this variant has been classified as Pathogenic. - |
Retinitis pigmentosa Pathogenic:1
Pathogenic, no assertion criteria provided | research | NIHR Bioresource Rare Diseases, University of Cambridge | Jan 01, 2015 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at